Abbott (NYSE:ABT) announced that it received FDA emergency use authorization (EUA) for what it touts as the fastest available molecular point-of-care test for detecting COVID-19. The test, which Abbott says can deliver positive results in as little as five minutes and negative results in 13 minutes, is slated to run on the company’s ID Now platform […]
5 companies on the front lines of the coronavirus fight
Nancy Crotti, Managing Editor and Danielle Kirsh, Senior Editor Amid the stock market roller-coaster ride that began last month, medtech companies that make devices and diagnostic tests vital to fighting COVID-19 may ultimately fare better than others, but it’s hard to tell until the virus peaks and people get back to work. At midafternoon today, […]
7 ways the coronavirus is affecting medtech
Medtech companies face some tough times as the deadly coronavirus pandemic gains steam. But could this be the medical device industry’s Dunkirk, too? Just days ago, MassMEDIC president Brian Johnson made a call-out on LinkedIn for people to send ideas about how Massachusetts medical device companies could help fight COVID-19. He drew an analogy to […]
Abbott receives FDA emergency use authorization for coronavirus test
Abbott (NYSE:ABT) has received FDA emergency use authorization for a molecular test for novel coronavirus (COVID-19). The company said yesterday that it will immediately ship 150,000 of its RealTime SARS-CoV-2 EUA tests to existing customers in the U.S. Customers can use the tests on Abbott’s m2000 RealTime system, and Abbott will deploy additional m2000 systems as needed. […]
How will coronavirus affect medtech companies that rely on elective surgeries?
One thing is likely to hurt some medtech companies more than others during the coronavirus pandemic: an elective surgical procedure slowdown. This thought had begun to emerge last week among industry watchers, but a pair of tweets over the weekend gained thousands of “likes” and retweets. The American College of Surgeons called for hospitals to […]
U.K. court bars Edwards TMVR sales, gives Abbott win in patent spat
A judge in the England issued an injunction yesterday barring Edwards Lifesciences from selling its Pascal transcatheter mitral valve repair (TMVR) device in the U.K. A different judge had previously denied Abbott’s petition for such an injunction. Yesterday, Judge Colin Birss of the High Court of England and Wales also ruled that two patents held […]
Medical device company stocks aren’t immune from coronavirus
Major U.S. medical device company stocks have generally performed as poorly as others over the past two weeks as the global coronavirus outbreak drive markets down. Among 20 of the largest U.S. companies on Medical Design & Outsourcing and MassDevice‘s annual Big 100 list, both the average and median decline in price was roughly 17% […]
Abbott wins CE Mark for FlexNav delivery system
Abbott (NYSE:ABT) announced today that it won CE Mark approval in Europe for the FlexNav delivery system for its Portico transcatheter aortic valve implantation (TAVI) system. The Abbott Park, Ill.-based company’s FlexNav delivery system is designed to offer another tool for doctors to treat patients requiring a transcatheter aortic valve implant by incorporating stability, predictability and […]
Abbott touts real-world data around FreeStyle Libre system
Abbott (NYSE:ABT) recently announced that new real-world data shows that users of its FreeStyle Libre continuous glucose monitor (CGM) have improved on four different fronts. Users of the Abbott Park, Ill.–based company’s device showed better glucose control, increased time in target glucose range, decreased time in hyperglycemia and hypoglycemia and reduced HbA1C (average glucose levels over […]
Judge tosses Abbott’s bid to dismiss Tendyne investors’ $50m claim
Abbott (NYSE:ABT) has lost a bid to dismiss a lawsuit by former investors in Tendyne Holdings, who claim that the healthcare giant dragged its heels on obtaining a regulatory approval that would have triggered a $50 million milestone payment. Abbott in September 2015 paid $225 million up front for the stake it didn’t already own in […]
FDA: Abbott recall of coronary dilation catheters is serious
An Abbott (NYSE:ABT) recall of certain coronary dilation catheters is Class I — the most serious type of recall, FDA said today. The recall, which Abbott originally announced Jan. 29, involves nearly 14,000 NC Trek RX coronary dilatation catheters and NC Traveler RX coronary dilatation catheters with 4.0 mm, 4.5 mm and 5.0 mm balloon diameters. […]
- 1
- 2
- 3
- …
- 73
- Next Page »
